1. Very low-depth sequencing in a founder population identifies a cardioprotective APOC3 signal missed by genome-wide imputation.
- Author
-
Gilly A, Ritchie GR, Southam L, Farmaki AE, Tsafantakis E, Dedoussis G, and Zeggini E
- Subjects
- Alleles, Cardiovascular Diseases blood, Cardiovascular Diseases pathology, Female, Founder Effect, Genetics, Population, Genome, Human, Genome-Wide Association Study, Genotype, Greece, Humans, Male, Mutation, Polymorphism, Single Nucleotide, Triglycerides blood, White People genetics, Apolipoprotein C-III genetics, Cardiovascular Diseases genetics, High-Throughput Nucleotide Sequencing, Triglycerides genetics
- Abstract
Cohort-wide very low-depth whole-genome sequencing (WGS) can comprehensively capture low-frequency sequence variation for the cost of a dense genome-wide genotyping array. Here, we analyse 1x sequence data across the APOC3 gene in a founder population from the island of Crete in Greece (n = 1239) and find significant evidence for association with blood triglyceride levels with the previously reported R19X cardioprotective null mutation (β = -1.09,σ = 0.163, P = 8.2 × 10
-11 ) and a second loss of function mutation, rs138326449 (β = -1.17,σ = 0.188, P = 1.14 × 10-9 ). The signal cannot be recapitulated by imputing genome-wide genotype data on a large reference panel of 5122 individuals including 249 with 4x WGS data from the same population. Gene-level meta-analysis with other studies reporting burden signals at APOC3 provides robust evidence for a replicable cardioprotective rare variant aggregation (P = 3.2 × 10-31 , n = 13 480)., (© The Author 2016. Published by Oxford University Press.)- Published
- 2016
- Full Text
- View/download PDF